News | MLL

Our newsletter is an offer of MLL Münchner Leukämielabor GmbH, Max-Lebsche-Platz 31, 81377 Munich (“MLL,” “we”) and contains information about our products and services, research results, events and other news relevant to the company and to the discipline, especially regarding diagnostics and subsequent therapy for leukemia and lymphoma. For you to subscribe, we need the e-mail address that you want us to send the newsletter to. We may use optional information to personalize how the addressee is addressed.
To continuously improve the quality of our newsletter and its contents, we conduct a pseudonymized analysis of the opening rate of the newsletter and information on calling up specific articles. You can find detailed information on how personal data is processed in connection with our newsletter in our Data protection information section.

By clicking on the “Subscribe to the newsletter” button, I consent to allow MLL to use the e-mail address and optional information provided by me for sending the newsletter and for addressing me personally.

You have the right to withdraw your consent at any time. Withdrawing your consent does not affect the lawfulness of the processing that took place based on your consent up until the time of withdrawal. One way you can withdraw your consent is by using the withdrawal function contained in every newsletter. Alternatively, you can declare that you are withdrawing your consent by sending an e-mail to presse@remove-this.mll.com or by mailing a letter to MLL Münchner Leukämielabor GmbH, Max-Lebsche-Platz 31, 81377 Munich.

Here you will find all MLL News as well as scientific contributions to leukemia diagnostics and research.

to the MLL Magazine

Prof. Dr. med. Dr. phil. Torsten Haferlach
from 30.09.2020
Automation & Artificial Intelligence
BELUGA - A Prospective, Registered Study on the Use of Artificial Intelligence (AI) in Hematology
Even before the start of the COVID-19 pandemic, we saw how strongly digitalization is shaping our private and professional lives and will continue to do so in the future. This also applies to innovations for daily work in the paperless Munich Leukemia Laboratory (MLL), such as the complete digitalization of all medical findings in a constantly improving digital infrastructure. However, AI will mark a new era for medical diagnostic services as well.
Post review
Current rating is 5.0 out of 5

1

2

3

4

5
Read article
Dr. med. Christian Pohlkamp
from 30.09.2020
MLL News
On our own behalf: Optimizing the quality of service
It is our job to offer you the current repertoire of state-of-the-art leukemia diagnostic services in the Munich Leukemia Laboratory (MLL). To fully optimize the diagnostic process, the integrity of the sample collected is of great importance, both to provide reliable test results and to apply the requisite methods within the operating workflow. So that we may always be able to best serve you as the sender of the sample and the affected patients, we would like to explain some important aspects of the pre-analytical phase, which includes blood and bone marrow sample collection, handling and transport to the laboratory.
Post review
Current rating is 5.0 out of 5

1

2

3

4

5
Read article